Trial intelligence / Profile preview

Etoricoxib vs Ibuprofen in Osteoarthritis

NCT00092755Phase 3Completed

Sponsor
Organon & Co.
Start
Apr 2003
Primary completion
Nov 2003
Modality
Small Molecules
01

Overview

Phase 3, randomised, double-blind trial of etoricoxib in osteoarthritis (OA) (3 arms), sponsored by Organon & Co. Primary endpoints: WOMAC VA 3.0 pain subscale at 12 weeks, WOMAC VA 3.0 physical function subscale at 12 weeks and 1 more. Started Apr 2003; status: completed.

02

Drugs

etoricoxib
03

Conditions

osteoarthritis (OA)

Beyond the preview

Go deeper on NCT00092755.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00092755.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call